PALOMA-2

A Study of Amivantamab in Participants with Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Study Name:
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PALOMA-2)

Targeted Disease(s):
Lung Cancer

Purpose of Study:

The primary objectives are to assess anti-tumor activity (objective response rate [ORR]) (Cohorts 1, 2, and 3) and to evaluate the safety (Cohort 4) of amivantamab SC-CF via manual injection.

Study Dates:
December 2, 2022 - May 31, 2024

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Janssen Research & Development, LLC

Sponsors:

Janssen Research & Development, LLC

Contact:

Phone: 1-844-434-4210
Email: [email protected]

ClinicalTrails.gov Identifier:
NCT05498428

Register for Trial
Asthma Educator Institute
, | Jul 11, 2022
Community Connections - RSV: The Illness on Every Parent's Radar This Season
, | Feb 08, 2023